RxDoctor Payments Data

Sheenal Patel, MD

Allergy & Immunology · Willow Grove, PANPI 1376806992

Payments from drug & device makers

$3,023in general payments, 2019–2025

Across 145 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$561
  • GSK$492
  • Blueprint Medicines Corporation$275
  • Regeneron Healthcare Solutions, Inc.$207
  • CSL Behring$158
  • Amgen$131
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,010100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,023 in reported general payments places this provider in the 50th percentile of 175 allergy & immunology providers in Pennsylvania.

See all allergy & immunology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$339,465
Medicare patients
334
Services billed
14,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab12$135,450
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$53,358
XolairOmalizumab17$49,814
Breo ElliptaFluticasone/Vilanterol26$18,216
Advair HfaFluticasone Propion/Salmeterol14$10,160
Arnuity ElliptaFluticasone Furoate23$6,402
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$4,525
Ipratropium Bromide131$4,005
Epinephrine28$3,858
Albuterol Sulfate HfaAlbuterol Sulfate55$1,123
Fluticasone Propionate53$1,080
Azelastine Hcl33$657
Levocetirizine Dihydrochloride19$607
Montelukast Sodium50$543
Famotidine36$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$492$213,426122 claims
Hikma Pharmaceuticals USAEpinephrine$68$3,85828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 175 allergy & immunology providers in Pennsylvania.

Other allergy & immunology in Willow Grove

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →